Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
The New England Journal of Medicine
|
July 3, 1999
Mechanism of intravenous immune globulin therapy
B Spellberg
Life Sciences
|
September 19, 2000
The cutaneous citadel: a holistic view of skin and immunity
B Spellberg
Clinical Pharmacology and Therapeutics
|
July 25, 2014
Prioritized current unmet needs for antibacterial therapies
B Spellberg, D Shlaes
Hematology/Oncology Clinics of North America
|
November 30, 1999
Autologous bone marrow transplantation in acute leukemia
B Spellberg, G J Schiller
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 19, 2000
Type 1/Type 2 immunity in infectious diseases
B Spellberg, J E Edwards
Clinical Pharmacology and Therapeutics
|
September 15, 2016
Regulatory Pathways for New Antimicrobial Agents: Trade-offs to Keep the Perfect From Being the Enemy of the Good
B Spellberg, K A Marr, E P Brass
Archives of Internal Medicine
|
December 1, 2001
mtDNA disease in the primary care setting
B Spellberg, R M Carroll, E Robinson, et al.
Infection and Immunity
|
November 1, 1995
Reduced virulence of Candida albicans PHR1 mutants
M A Ghannoum, B Spellberg, S M Saporito-Irwin, et al.
Infection
|
June 15, 2007
Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development
B Spellberg, L G Miller, M N Kuo, et al.
The Journal of Clinical Investigation
|
January 15, 1997
Interferon-gamma differentially regulates interleukin-12 and interleukin-10 production in leprosy
D H Libraty, L E Airan, K Uyemura, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
The New England Journal of Medicine
|
July 3, 1999
Mechanism of intravenous immune globulin therapy
B Spellberg
Life Sciences
|
September 19, 2000
The cutaneous citadel: a holistic view of skin and immunity
B Spellberg
Clinical Pharmacology and Therapeutics
|
July 25, 2014
Prioritized current unmet needs for antibacterial therapies
B Spellberg, D Shlaes
Hematology/Oncology Clinics of North America
|
November 30, 1999
Autologous bone marrow transplantation in acute leukemia
B Spellberg, G J Schiller
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 19, 2000
Type 1/Type 2 immunity in infectious diseases
B Spellberg, J E Edwards
Clinical Pharmacology and Therapeutics
|
September 15, 2016
Regulatory Pathways for New Antimicrobial Agents: Trade-offs to Keep the Perfect From Being the Enemy of the Good
B Spellberg, K A Marr, E P Brass
Archives of Internal Medicine
|
December 1, 2001
mtDNA disease in the primary care setting
B Spellberg, R M Carroll, E Robinson, et al.
Infection and Immunity
|
November 1, 1995
Reduced virulence of Candida albicans PHR1 mutants
M A Ghannoum, B Spellberg, S M Saporito-Irwin, et al.
Infection
|
June 15, 2007
Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development
B Spellberg, L G Miller, M N Kuo, et al.
The Journal of Clinical Investigation
|
January 15, 1997
Interferon-gamma differentially regulates interleukin-12 and interleukin-10 production in leprosy
D H Libraty, L E Airan, K Uyemura, et al.
Page
of 2